BCL2 gene codes for an antiapoptotic protein and its prime role in CLL contribution have been used by the drug called venetoclax, which targets BCL2 leading to a good response in the CLL patients [6]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.